About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Nebivolol in Patients With Systolic Stage 2 Hypertension

NCT01057251·36 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Forest Laboratories

Age

18–64

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

male of female, 18 to 64 years of age at screening
mean seated heart rate at least 60 bpm
diagnosed systolic stage 2 hypertension
unremarkable physical exam findings

You may not be if

high risk due to secondary hypertension or former stage 3 hypertension by JNC6
concurrent conditions (reno, cardiovascular, obesity, thyroid, etc)
currently taking medication that cannot be stopped during the course of the study
participating other clinical trials
member of the study center personnel
documented drug abuse
contra indication to beta blocker
abnormal lab finding
poor compliance
other conditions judged by investigator that is not suitable for the study

The record

StatusCompleted

PhasePhase 4

Taking part433

StartedMar 2010

UpdatedJan 11, 2012

Conditions

Where36

Forest Investigative Site 008
Foley, Alabama, United States
Forest Investigative Site 021
Montgomery, Alabama, United States
Forest Investigative Site 006
Chino, California, United States

Clareo Health | Nebivolol in Patients With Systolic Stage 2 Hypertension